Cargando…
GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition
Since December 2019, SARS-CoV-2 has spread quickly worldwide, leading to more than 280 million confirmed cases, including over 5,000,000 deaths. Interestingly, coronaviruses were found to subvert and hijack autophagic process to allow their viral replication. Autophagy-modulating compounds thus rapi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778678/ https://www.ncbi.nlm.nih.gov/pubmed/35062337 http://dx.doi.org/10.3390/v14010132 |
_version_ | 1784637381798789120 |
---|---|
author | Bestion, Eloïne Zandi, Keivan Belouzard, Sandrine Andreani, Julien Lepidi, Hubert Novello, Marie Rouquairol, Clara Baudoin, Jean-Pierre Rachid, Madani La Scola, Bernard Mege, Jean-Louis Dubuisson, Jean Schinazi, Raymond F. Mezouar, Soraya Halfon, Philippe |
author_facet | Bestion, Eloïne Zandi, Keivan Belouzard, Sandrine Andreani, Julien Lepidi, Hubert Novello, Marie Rouquairol, Clara Baudoin, Jean-Pierre Rachid, Madani La Scola, Bernard Mege, Jean-Louis Dubuisson, Jean Schinazi, Raymond F. Mezouar, Soraya Halfon, Philippe |
author_sort | Bestion, Eloïne |
collection | PubMed |
description | Since December 2019, SARS-CoV-2 has spread quickly worldwide, leading to more than 280 million confirmed cases, including over 5,000,000 deaths. Interestingly, coronaviruses were found to subvert and hijack autophagic process to allow their viral replication. Autophagy-modulating compounds thus rapidly emerged as an attractive strategy to fight SARS-CoV-2 infection, including the well-known chloroquine (CQ). Here, we investigated the antiviral activity and associated mechanism of GNS561/Ezurpimtrostat, a small lysosomotropic molecule inhibitor of late-stage autophagy. Interestingly, GNS561 exhibited antiviral activity of 6–40 nM depending on the viral strain considered, currently positioning it as the most powerful molecule investigated in SARS-CoV-2 infection. We then showed that GNS561 was located in lysosome-associated-membrane-protein-2-positive (LAMP2-positive) lysosomes, together with SARS-CoV-2. Moreover, GNS561 increased LC3-II spot size and caused the accumulation of autophagic vacuoles and the presence of multilamellar bodies, suggesting that GNS561 disrupted the autophagy mechanism. To confirm our findings, we used the K18-hACE2 mouse model and highlighted that GNS561 treatment led to a decline in SARS-CoV-2 virions in the lungs associated with a disruption of the autophagy pathway. Overall, our study highlights GNS561 as a powerful drug in the treatment of SARS-CoV-2 infection and supports the hypothesis that autophagy blockers could be an alternative strategy for COVID-19. |
format | Online Article Text |
id | pubmed-8778678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87786782022-01-22 GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition Bestion, Eloïne Zandi, Keivan Belouzard, Sandrine Andreani, Julien Lepidi, Hubert Novello, Marie Rouquairol, Clara Baudoin, Jean-Pierre Rachid, Madani La Scola, Bernard Mege, Jean-Louis Dubuisson, Jean Schinazi, Raymond F. Mezouar, Soraya Halfon, Philippe Viruses Article Since December 2019, SARS-CoV-2 has spread quickly worldwide, leading to more than 280 million confirmed cases, including over 5,000,000 deaths. Interestingly, coronaviruses were found to subvert and hijack autophagic process to allow their viral replication. Autophagy-modulating compounds thus rapidly emerged as an attractive strategy to fight SARS-CoV-2 infection, including the well-known chloroquine (CQ). Here, we investigated the antiviral activity and associated mechanism of GNS561/Ezurpimtrostat, a small lysosomotropic molecule inhibitor of late-stage autophagy. Interestingly, GNS561 exhibited antiviral activity of 6–40 nM depending on the viral strain considered, currently positioning it as the most powerful molecule investigated in SARS-CoV-2 infection. We then showed that GNS561 was located in lysosome-associated-membrane-protein-2-positive (LAMP2-positive) lysosomes, together with SARS-CoV-2. Moreover, GNS561 increased LC3-II spot size and caused the accumulation of autophagic vacuoles and the presence of multilamellar bodies, suggesting that GNS561 disrupted the autophagy mechanism. To confirm our findings, we used the K18-hACE2 mouse model and highlighted that GNS561 treatment led to a decline in SARS-CoV-2 virions in the lungs associated with a disruption of the autophagy pathway. Overall, our study highlights GNS561 as a powerful drug in the treatment of SARS-CoV-2 infection and supports the hypothesis that autophagy blockers could be an alternative strategy for COVID-19. MDPI 2022-01-12 /pmc/articles/PMC8778678/ /pubmed/35062337 http://dx.doi.org/10.3390/v14010132 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bestion, Eloïne Zandi, Keivan Belouzard, Sandrine Andreani, Julien Lepidi, Hubert Novello, Marie Rouquairol, Clara Baudoin, Jean-Pierre Rachid, Madani La Scola, Bernard Mege, Jean-Louis Dubuisson, Jean Schinazi, Raymond F. Mezouar, Soraya Halfon, Philippe GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition |
title | GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition |
title_full | GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition |
title_fullStr | GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition |
title_full_unstemmed | GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition |
title_short | GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition |
title_sort | gns561 exhibits potent antiviral activity against sars-cov-2 through autophagy inhibition |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778678/ https://www.ncbi.nlm.nih.gov/pubmed/35062337 http://dx.doi.org/10.3390/v14010132 |
work_keys_str_mv | AT bestioneloine gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT zandikeivan gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT belouzardsandrine gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT andreanijulien gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT lepidihubert gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT novellomarie gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT rouquairolclara gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT baudoinjeanpierre gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT rachidmadani gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT lascolabernard gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT megejeanlouis gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT dubuissonjean gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT schinaziraymondf gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT mezouarsoraya gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition AT halfonphilippe gns561exhibitspotentantiviralactivityagainstsarscov2throughautophagyinhibition |